Collaboration with Thermo Fisher

AI SummaryClose X

GENinCode Plc has announced a significant collaboration with Thermo Fisher Scientific to commercialize its CARDIO inCode-Score® Polygenic Risk Score test for coronary heart disease prediction and prevention. This agreement includes manufacturing, sales, and distribution across the US and EMEA regions, with the test initially available as a Lab Developed Test before US FDA approval. The collaboration leverages Thermo Fisher's QuantStudio™ 5 Dx Real-Time PCR System and aims to address the substantial US$22.8 billion and Euro€12.5 billion cardiovascular devices markets. The CARDIO inCode-Score® test has secured New York State licensure and will be included in the 2025 Clinical Laboratory Fee Schedule with an average reimbursement of approximately $500.00 per test, while GENinCode expects to submit additional data to the FDA in Q1 2026.

Disclaimer*

Companies

GENinCode (GENI)
UK 100

Latest directors dealings